{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:55:58Z","timestamp":1791381358939,"version":"4.3.3"},"reference-count":117,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1111\/jth.15217","type":"journal-article","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T09:38:43Z","timestamp":1608111523000},"page":"892-908","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Monitoring of anticoagulation in thrombotic antiphospholipid syndrome"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2032-390X","authenticated-orcid":false,"given":"Hannah","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9704-2845","authenticated-orcid":false,"given":"Maria","family":"Efthymiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7559-2579","authenticated-orcid":false,"given":"Katrien M.J.","family":"Devreese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1111\/jth.15217_bb0010","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1111\/jth.15217_bb0015","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/jth.13976","article-title":"the Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibodies. Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH","volume":"16","author":"Devreese","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15217_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.05.007","article-title":"The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review","volume":"92","author":"Cervera","year":"2018","journal-title":"J Autoimmun"},{"issue":"7","key":"10.1111\/jth.15217_bb0025","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/rheumatology\/key082","article-title":"The effect of triple therapy on the mortality of catastrophic anti\u2010phospholipid syndrome patients","volume":"57","author":"Rodr\u00edguez\u2010Pint\u00f3","year":"2018","journal-title":"Rheumatology"},{"issue":"1","key":"10.1111\/jth.15217_bb0030","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1001\/archinte.164.1.77","article-title":"High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus","volume":"164","author":"Ruiz\u2010Irastorza","year":"2004","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1111\/jth.15217_bb0035","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients: Clinical and Immunologic Manifestations of APS","volume":"46","author":"Cervera","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1111\/jth.15217_bb0040","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1002\/acr.22066","volume":"65","author":"Andreoli","year":"2013","journal-title":"Arthritis Care Res"},{"issue":"19","key":"10.1111\/jth.15217_bb0045","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1182\/blood-2017-09-805689","article-title":"Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism","volume":"131","author":"Kearon","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1111\/jth.15217_bb0050","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/jth.14720","article-title":"Prevalence of confirmed antiphospholipid syndrome in 18\u201350 years unselected patients with first unprovoked venous thromboembolism","volume":"18","author":"Miranda","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"11","key":"10.1111\/jth.15217_bb0055","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1136\/annrheumdis-2014-205663","article-title":"The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review","volume":"74","author":"Sciascia","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1111\/jth.15217_bb0060","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/art.40901","article-title":"The Epidemiology of Antiphospholipid Syndrome: A Population\u2010Based Study","volume":"71","author":"Duarte\u2010Garc\u00eda","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1111\/jth.15217_bb0065","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1111\/jth.14935","article-title":"Use of Direct Oral Anticoagulants in Patients with Thrombotic Antiphospholipid Syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis","volume":"18","author":"Zuily","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15217_bb0070","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1177\/0961203320950461","article-title":"16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends","volume":"29","author":"Cohen","year":"2020","journal-title":"Lupus"},{"issue":"10","key":"10.1111\/jth.15217_bb0075","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/jth.15217_bb0080","doi-asserted-by":"crossref","unstructured":"Drebes AB, Gates C, Maguire F.Anticoagulants and antiplatelet agents in pregnancy. In: Disorders of Thrombosis and Haemostasis in Pregnancy. A guide to management; Eds H Cohen and P O\u2019Brien. 2nd edition. Springer\u2010Verlag, London, 2015, p 15\u201339.","DOI":"10.1007\/978-3-319-15120-5_2"},{"issue":"8","key":"10.1111\/jth.15217_bb0085","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/jth.14192","article-title":"McMaster RARE\u2010Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome","volume":"16","author":"Legault","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"11","key":"10.1111\/jth.15217_bb0090","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1111\/jth.13481","article-title":"Monitoring patients with the lupus anticoagulant while treated with vitamin K antagonists: communication from the SSC of the ISTH","volume":"14","author":"Tripodi","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1111\/jth.15217_bb0095","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.thromres.2015.03.030","article-title":"Thrombin generation and factor X assays for the assessment of warfarin anticoagulation in thrombotic antiphospholipid syndrome","volume":"135","author":"Efthymiou","year":"2015","journal-title":"Thromb Res"},{"issue":"3","key":"10.1111\/jth.15217_bb0100","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1046\/j.1365-2141.2001.03178.x","article-title":"Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins","volume":"115","author":"Tripodi","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.15217_bb0105","first-page":"1","article-title":"Standardization of Prothrombin Time\/International Normalized Ratio (PT\/INR)","volume":"2","author":"Dorgalaleh","year":"2020","journal-title":"Int J Lab Hematol"},{"issue":"10","key":"10.1111\/jth.15217_bb0110","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1515\/cclm-2017-0976","article-title":"International normalized ratio (INR) testing in Europe: between\u2010laboratory comparability of test results obtained by Quick and Owren reagents","volume":"56","author":"Meijer","year":"2018","journal-title":"Clin Chem Lab Med CCLM"},{"issue":"2","key":"10.1111\/jth.15217_bb0115","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1538-7836.2011.04568.x","article-title":"Precision and accuracy of point\u2010of\u2010care testing coagulometers used for self\u2010testing and self\u2010management of oral anticoagulation therapy: Point\u2010of\u2010care coagulometers","volume":"10","author":"Christensen","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15217_bb0120","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1055\/s-0038-1657371","article-title":"Calibration of reference thromboplastins and standardisation of the prothrombin time ratio","volume":"49","author":"Kirkwood","year":"1983","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1111\/jth.15217_bb0125","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2141.2011.08753.x","article-title":"Guidelines on oral anticoagulation with warfarin \u2010 fourth edition: Guideline","volume":"154","author":"Keeling","year":"2011","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1111\/jth.15217_bb0130","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.thromres.2011.08.027","article-title":"The clinical significance of differences between point\u2010of\u2010care and laboratory INR methods in over\u2010anticoagulated patients","volume":"130","author":"Lawrie","year":"2012","journal-title":"Thromb Res"},{"issue":"22","key":"10.1111\/jth.15217_bb0135","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1182\/bloodadvances.2018024893","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy","volume":"2","author":"Witt","year":"2018","journal-title":"Blood Adv"},{"issue":"5","key":"10.1111\/jth.15217_bb0140","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bjh.13070","article-title":"the BCSH Committee. Patient self\u2010testing and self\u2010management of oral anticoagulation with vitamin K antagonists: guidance from the British Committee for Standards in Haematology","volume":"167","author":"Jennings","year":"2014","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1111\/jth.15217_bb0145","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1515\/cclm-2014-0906","article-title":"Interference of C\u2010reactive protein with clotting times","volume":"53","author":"Devreese","year":"2015","journal-title":"Clin Chem Lab Med"},{"issue":"3","key":"10.1111\/jth.15217_bb0150","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.thromres.2007.05.006","article-title":"Detection of shortened activated partial thromboplastin times: An evaluation of different commercial reagents","volume":"121","author":"ten Boekel","year":"2007","journal-title":"Thromb Res"},{"key":"10.1111\/jth.15217_bb0155","first-page":"17","article-title":"College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy","volume":"122","author":"Olson","year":"1998","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"10.1111\/jth.15217_bb0160","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/MBC.0b013e328304e066","article-title":"Comparison of a chromogenic factor X assay with international normalized ratio for monitoring oral anticoagulation therapy","volume":"19","author":"McGlasson","year":"2008","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"2","key":"10.1111\/jth.15217_bb0165","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.biopha.2009.09.020","article-title":"Usefulness of factor II and factor X as therapeutic markers in patients under chronic warfarin therapy","volume":"64","author":"Costa","year":"2010","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"10.1111\/jth.15217_bb0170","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/bjh.12975","article-title":"the BCSH committee. Measurement of non\u2010Coumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology","volume":"166","author":"Kitchen","year":"2014","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1111\/jth.15217_bb0175","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/17474086.2017.1345306","article-title":"Therapeutic monitoring of unfractionated heparin \u2013 trials and tribulations","volume":"10","author":"Baluwala","year":"2017","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"10.1111\/jth.15217_bb0180","first-page":"1122","article-title":"Anti\u2010Xa monitoring: inter\u2010assay variability","volume":"84","author":"Depasse","year":"2000","journal-title":"Thromb Haemost"},{"issue":"11","key":"10.1111\/jth.15217_bb0185","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1515\/cclm-2020-0130","article-title":"Quality performance for indirect Xa inhibitor monitoring in patients using international external quality data","volume":"58","author":"Hollestelle","year":"2020","journal-title":"Clin Chem Lab Med"},{"issue":"03","key":"10.1111\/jth.15217_bb0190","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1055\/s-0038-1627480","article-title":"International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants","volume":"118","author":"Gosselin","year":"2018","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1111\/jth.15217_bb0195","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1373\/clinchem.2015.248625","article-title":"Thrombin Generation Assay and Its Application in the Clinical Laboratory","volume":"62","author":"Tripodi","year":"2016","journal-title":"Clin Chem"},{"issue":"10","key":"10.1111\/jth.15217_bb0200","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1111\/j.1538-7836.2008.03117.x","article-title":"High rate of unprovoked recurrent venous thrombosis is associated with high thrombin\u2010generating potential in a prospective cohort study","volume":"6","author":"Besser","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"8","key":"10.1111\/jth.15217_bb0205","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1111\/jth.14863","article-title":"Towards standardization of thrombin generation assays: Inventory of thrombin generation methods based on results of an International Society of Thrombosis and Haemostasis Scientific Standardization Committee survey","volume":"18","author":"de Laat\u2010Kremers","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15217_bb0210","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/jth.14470","article-title":"Assessment of the analytical performances and sample stability on ST Genesia system using the STG \u2010DrugScreen application","volume":"17","author":"Douxfils","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15217_bb0215","article-title":"Thrombotic antiphospholipid syndrome: A practical guide to diagnosis and management","author":"Sayar","year":"2020","journal-title":"Thromb Res"},{"issue":"1","key":"10.1111\/jth.15217_bb0220","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000924","article-title":"Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"5","author":"Tektonidou","year":"2019","journal-title":"RMD Open"},{"issue":"2","key":"10.1111\/jth.15217_bb0225","doi-asserted-by":"crossref","first-page":"44S","DOI":"10.1378\/chest.11-2292","article-title":"Oral anticoagulant therapy. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence\u2010Based Clinical Practice Guidelines","volume":"141","author":"Ageno","year":"2012","journal-title":"Chest"},{"issue":"2","key":"10.1111\/jth.15217_bb0230","doi-asserted-by":"crossref","first-page":"24S","DOI":"10.1378\/chest.11-2291","article-title":"Weitz, Samama MM. Parenteral Anticoagulants","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"key":"10.1111\/jth.15217_bb0235","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1177\/0961203309106832","article-title":"The Euro\u2010Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe","volume":"18","author":"Cervera","year":"2009","journal-title":"Lupus"},{"issue":"9","key":"10.1111\/jth.15217_bb0240","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1111\/jth.13763","article-title":"Thrombotic risk stratification by platelet count in patients with antiphospholipid antibodies: a longitudinal study","volume":"15","author":"Hisada","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1111\/jth.15217_bb0245","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/jth.13535","article-title":"Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH: reply","volume":"15","author":"Cohen","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1111\/jth.15217_bb0250","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1046\/j.1365-2141.1997.3283145.x","article-title":"Monitoring of oral anticoagulant therapy in lupus anticoagulant positive patients with the anti\u2010phospholipid syndrome","volume":"98","author":"Lawrie","year":"1997","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1111\/jth.15217_bb0255","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1177\/0961203314558859","article-title":"Lupus anticoagulant\u2010hypoprothrombinemia syndrome: report of two cases and review of the literature","volume":"24","author":"Mulliez","year":"2015","journal-title":"Lupus"},{"issue":"5","key":"10.1111\/jth.15217_bb0260","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/ijlh.12523","article-title":"Evaluation of a new PT\u2010INR monitoring system in patients with the antiphospholipid syndrome","volume":"38","author":"Braham","year":"2016","journal-title":"Int J Lab Hematol"},{"issue":"6","key":"10.1111\/jth.15217_bb0265","first-page":"1196","article-title":"Point\u2010of\u2010care testing of the international normalized ratio in patients with antiphospholipid antibodies","volume":"94","author":"Perry","year":"2005","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1111\/jth.15217_bb0270","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/POC.0000000000000149","article-title":"Accuracy of CoaguChek XS in Patients With Antiphospholipid Syndrome","volume":"16","author":"Taylor","year":"2017","journal-title":"Point Care"},{"issue":"8","key":"10.1111\/jth.15217_bb0275","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s00277-015-2374-3","article-title":"Monitoring anticoagulant therapy with vitamin K antagonists in patients with antiphospholipid syndrome","volume":"94","author":"Isert","year":"2015","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1111\/jth.15217_bb0280","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1365-2141.2004.05300.x","article-title":"Patient self\u2010testing is a reliable and acceptable alternative to laboratory INR monitoring","volume":"128","author":"Gardiner","year":"2005","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1111\/jth.15217_bb0285","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1177\/1060028014546361","article-title":"Warfarin Monitoring in Antiphospholipid Syndrome and Lupus Anticoagulant","volume":"48","author":"Crowl","year":"2014","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1111\/jth.15217_bb0290","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/MBC.0000000000000030","article-title":"Monitoring anticoagulation in patients with an unreliable prothrombin time\/international normalized ratio: factor II versus chromogenic factor X testing","volume":"25","author":"Baumann Kreuziger","year":"2014","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"3","key":"10.1111\/jth.15217_bb0295","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MBC.0b013e32833581a3","article-title":"Factor X and factor II activity levels do not always agree in warfarin\u2010treated lupus anticoagulant patients","volume":"21","author":"Rosborough","year":"2010","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"01","key":"10.1111\/jth.15217_bb0300","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1160\/TH08-06-0393","article-title":"Laboratory detection of the antiphospholipid syndrome via calibrated automated thrombography","volume":"101","author":"Devreese","year":"2009","journal-title":"Thromb Haemost"},{"issue":"12","key":"10.1111\/jth.15217_bb0305","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"van Es","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1111\/jth.15217_bb0310","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1177\/1358863X16668588","article-title":"Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE\u2010COVER\u00ae, RE\u2010COVERTM II, and RE\u2010MEDYTM","volume":"21","author":"Goldhaber","year":"2016","journal-title":"Vasc Med"},{"issue":"13","key":"10.1111\/jth.15217_bb0315","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high\u2010risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"key":"10.1111\/jth.15217_bb0320","unstructured":"European Medicines Agency; EMA\/PRAC\/219985\/2019 Pharmacovigilance Risk Assessment Committee (PRAC) recommendations on signals. https:\/\/www.ema.europa.eu\/en\/documents\/prac\u2010recommendation\/prac\u2010recommendations\u2010signals\u2010adopted\u20108\u201011\u2010april\u20102019\u2010prac\u2010meeting_en.pdf (Accessed December 27 2019)"},{"issue":"1","key":"10.1111\/jth.15217_bb0325","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/jth.14674","article-title":"Use of direct oral anticoagulants in antiphospholipid syndrome: Reply","volume":"18","author":"Cohen","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1111\/jth.15217_bb0330","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1538-7836.2005.01166.x","article-title":"In vitro and in vivo studies of the novel antithrombotic agent BAY 59\u20137939\u2010an oral, direct Factor Xa inhibitor","volume":"3","author":"Perzborn","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"10","key":"10.1111\/jth.15217_bb0335","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1160\/TH16-04-0305","article-title":"Pregnancy outcome in patients exposed to direct oral anticoagulants \u2010 and the challenge of event reporting","volume":"116","author":"Beyer\u2010Westendorf","year":"2016","journal-title":"Thromb Haemost"},{"issue":"8","key":"10.1111\/jth.15217_bb0340","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1111\/jth.13366","article-title":"Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH","volume":"14","author":"Cohen","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"S1","key":"10.1111\/jth.15217_bb0345","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/ijlh.12992","article-title":"An update on laboratory assessment for direct oral anticoagulants (DOACs)","volume":"41","author":"Gosselin","year":"2019","journal-title":"Int J Lab Hematol"},{"key":"10.1111\/jth.15217_bb0350","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1111\/jth.15047","article-title":"Guidance from the Scientific and Standardization Committee for lupus anticoagulant\/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection and interpretation","volume":"18","author":"Devreese","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"7","key":"10.1111\/jth.15217_bb0355","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1111\/jth.14846","article-title":"Lupus anticoagulant detection in anticoagulated patients. Guidance from the Scientific and Standardization Committee for lupus anticoagulant\/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis","volume":"18","author":"Tripodi","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1111\/jth.15217_bb0360","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.thromres.2014.11.037","article-title":"Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in\u2010vivo markers of coagulation activation, in patients with venous thromboembolism","volume":"135","author":"Arachchillage","year":"2015","journal-title":"Thromb Res"},{"issue":"4","key":"10.1111\/jth.15217_bb0365","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/rth2.12332","article-title":"Inhibition of thrombin generation 12 hours after intake of direct oral anticoagulants","volume":"4","author":"Metze","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"9","key":"10.1111\/jth.15217_bb0370","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open\u2010label, phase 2\/3, non\u2010inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1111\/jth.15217_bb0375","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/rth2.12340","article-title":"Direct oral anticoagulant plasma levels and thrombin generation on ST Genesia system","volume":"4","author":"Pfrepper","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"10.1111\/jth.15217_bb0380","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"issue":"8","key":"10.1111\/jth.15217_bb0385","doi-asserted-by":"crossref","first-page":"E613","DOI":"10.1016\/S2352-3026(20)30116-2","article-title":"Management of anticoagulant\u2010refractory thrombotic antiphospholipid syndrome","volume":"7","author":"Cohen","year":"2020","journal-title":"Lancet Haematol"},{"issue":"22","key":"10.1111\/jth.15217_bb0390","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin\u2010induced thrombocytopenia","volume":"2","author":"Cuker","year":"2018","journal-title":"Blood Adv"},{"issue":"8","key":"10.1111\/jth.15217_bb0395","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s11606-016-3603-8","article-title":"Effects of Long\u2010Term Low\u2010Molecular\u2010Weight Heparin on Fractures and Bone Density in Non\u2010Pregnant Adults: A Systematic Review With Meta\u2010Analysis","volume":"31","author":"Gajic\u2010Veljanoski","year":"2016","journal-title":"J Gen Intern Med"},{"key":"10.1111\/jth.15217_bb0400","first-page":"1471","article-title":"Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study","volume":"126","author":"Jes\u00fas","year":"2018","journal-title":"BJOG Int J Obstet Gynaecol"},{"key":"10.1111\/jth.15217_bb0405","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1538-7836.2005.01185.x","article-title":"Primary antiphospholipid syndrome in pregnancy: an analysis of outcome in a cohort of 33 women treated with a rigorous protocol","volume":"3","author":"Stone","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"11","key":"10.1111\/jth.15217_bb0410","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1177\/0961203312451335","article-title":"Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: an observational study","volume":"21","author":"Fischer\u2010Betz","year":"2012","journal-title":"Lupus"},{"issue":"3","key":"10.1111\/jth.15217_bb0415","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/00313020126304","article-title":"A comparison of the sensitivity of APTT reagents to the effects of enoxaparin, a low\u2010molecular weight heparin","volume":"33","author":"Ip","year":"2001","journal-title":"Pathology"},{"issue":"11","key":"10.1111\/jth.15217_bb0420","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/bloodadvances.2019001373","article-title":"Comparing low\u2010molecular\u2010weight heparin dosing for treatment of venous thromboembolism in patients with obesity (RIETE registry)","volume":"4","author":"Mirza","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"10.1111\/jth.15217_bb0425","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/jth.14015","article-title":"Management of cancer\u2010associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH","volume":"16","author":"Samuelson Bannow","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15217_bb0430","unstructured":"Royal College of Obstetricians and Gynaecologists. Reducing the risk of venous thromboembolism during pregnancy and the puerperium. green\u2010top guideline no 37a. London RCOG; 2015. https:\/\/www.rcog.org.uk\/guidelines"},{"issue":"11","key":"10.1111\/jth.15217_bb0435","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1182\/blood-2014-09-551978","article-title":"How I treat catastrophic thrombotic syndromes","volume":"126","author":"Ortel","year":"2015","journal-title":"Blood"},{"key":"10.1111\/jth.15217_bb0440","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.athoracsur.2017.09.061","article-title":"The Society of Thoracic Surgeons, The Society of Cardiovascular Anesthesiologists, and The American Society of ExtraCorporeal Technology: Clinical Practice Guidelines\u2014Anticoagulation During Cardiopulmonary Bypass","volume":"105","author":"Shore\u2010Lesserson","year":"2018","journal-title":"Ann Thorac Surg"},{"issue":"2","key":"10.1111\/jth.15217_bb0445","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1001\/archinte.160.2.181","article-title":"A Meta\u2010analysis Comparing Low\u2010Molecular\u2010Weight Heparins With Unfractionated Heparin in the Treatment of Venous Thromboembolism: Examining Some Unanswered Questions Regarding Location of Treatment, Product Type, and Dosing Frequency","volume":"160","author":"Dolovich","year":"2000","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.1111\/jth.15217_bb0450","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1345\/aph.1M615","article-title":"Evaluation of Bleeding Risk in Patients Exposed to Therapeutic Unfractionated or Low\u2010Molecular Weight Heparin: A Cohort Study in the Context of a Quality Improvement Initiative","volume":"44","author":"Cossette","year":"2010","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1111\/jth.15217_bb0455","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1055\/s-0038-1650255","article-title":"The effects of long\u2010term heparin therapy during pregnancy on bone density. A prospective matched cohort study","volume":"75","author":"Douketis","year":"1996","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1111\/jth.15217_bb0460","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1365-2141.2010.08129.x","article-title":"Monitoring heparin anticoagulation in the acute phase response: Heparin Anticoagulation in the Acute Phase Response","volume":"149","author":"Uprichard","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.15217_bb0465","first-page":"17","article-title":"College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy","volume":"122","author":"Olson","year":"1998","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"10.1111\/jth.15217_bb0470","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/icvts\/ivt327","article-title":"Is there evidence that fresh frozen plasma is superior to antithrombin administration to treat heparin resistance in cardiac surgery?","volume":"18","author":"Beattie","year":"2014","journal-title":"Interact Cardiovasc Thorac Surg"},{"issue":"12","key":"10.1111\/jth.15217_bb0475","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1592\/phco.31.12.1221","article-title":"Strategies for Managing Heparin Therapy in Patients with Antiphospholipid Antibody Syndrome","volume":"31","author":"Mehta","year":"2011","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1111\/jth.15217_bb0480","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1111\/jocs.14557","article-title":"TEG improves anticoagulation management during cardiopulmonary bypass complicated by antiphospholipid syndrome","volume":"35","author":"Nakajima","year":"2020","journal-title":"J Card Surg"},{"key":"10.1111\/jth.15217_bb0485","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1177\/0961203319851863","article-title":"Four\u00ad year follow\u00adup of two patients on maintenance therapy with fondaparinux and mycophenolate mofetil for microthrombotic antiphospholipid syndrome","volume":"28","author":"Baron","year":"2019","journal-title":"Lupus"},{"key":"10.1111\/jth.15217_bb0490","unstructured":"Sayer Z, Burke S, Cohen H.The use of fondaparinux for recurrent thrombotic events. In: Research & Practice in Thrombosis and Haemostasis. July 2020. Abstract PB2410."},{"issue":"4","key":"10.1111\/jth.15217_bb0495","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s00223-002-2091-5","article-title":"Effects of fondaparinux compared with dalteparin, enoxaparin and unfractionated heparin on human osteoblasts","volume":"73","author":"Matziolis","year":"2003","journal-title":"Calcif Tissue Int"},{"key":"10.1111\/jth.15217_bb0500","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1056\/NEJM200404293501825","article-title":"Minor transplacental passage of fondaparinux in vivo","volume":"350","author":"Dempfle","year":"2004","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1111\/jth.15217_bb0505","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.thromres.2015.04.001","article-title":"Fondaparinux in pregnancy: Could it be a safe option? A review of the literature","volume":"135","author":"De Carolis","year":"2015","journal-title":"Thromb Res"},{"issue":"3","key":"10.1111\/jth.15217_bb0510","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1592\/phco.20.4.318.34881","article-title":"The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction","volume":"20","author":"Swan","year":"2000","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1111\/jth.15217_bb0515","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijoa.2009.01.012","article-title":"Anticoagulation with argatroban in a parturient with heparin\u2010induced thrombocytopenia","volume":"19","author":"Ekbatani","year":"2010","journal-title":"Int J Obstet Anesth"},{"issue":"4","key":"10.1111\/jth.15217_bb0520","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1447-0756.2011.01758.x","article-title":"Argatroban therapy for heparin\u2010induced thrombocytopenia during pregnancy in a woman with hereditary antithrombin deficiency","volume":"38","author":"Tanimura","year":"2012","journal-title":"J Obstet Gynaecol Res"},{"issue":"2","key":"10.1111\/jth.15217_bb0525","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1055\/s-0038-1651573","article-title":"Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans","volume":"69","author":"Fox","year":"1993","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1111\/jth.15217_bb0530","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1067\/mcp.2002.124522","article-title":"Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender","volume":"71","author":"Robson","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jth.15217_bb0535","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.thromres.2011.11.041","article-title":"Results of a consensus meeting on the use of argatroban in patients with heparin\u2010induced thrombocytopenia requiring antithrombolytic therapy \u2013 A European Perspective","volume":"129","author":"Alatri","year":"2012","journal-title":"Thromb Res"},{"issue":"6","key":"10.1111\/jth.15217_bb0540","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/ijlh.12414","article-title":"Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban","volume":"37","author":"Guy","year":"2015","journal-title":"Int J Lab Hematol"},{"issue":"4","key":"10.1111\/jth.15217_bb0545","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1309\/AJCPQOD9WFPEYY0H","article-title":"Measuring Direct Thrombin Inhibitors With Routine and Dedicated Coagulation Assays","volume":"138","author":"Curvers","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"10.1111\/jth.15217_bb0550","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1055\/s-2002-34305","article-title":"Monitoring of anticoagulation effects of direct thrombin inhibitors","volume":"28","author":"Fenyvesi","year":"2002","journal-title":"Sem Thromb Hemost"},{"issue":"1","key":"10.1111\/jth.15217_bb0555","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12871-018-0475-y","article-title":"Monitoring of argatroban and lepirudin anticoagulation in critically ill patients by conventional laboratory parameters and rotational thromboelastometry \u2013 a prospectively controlled randomized double\u2010blind clinical trial. Beiderlinden et al","volume":"18","author":"Beiderlinden","year":"2018","journal-title":"BMC Anesthesiol"},{"issue":"11\u201312","key":"10.1111\/jth.15217_bb0560","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.annfar.2004.11.003","volume":"25","author":"Salmi","year":"2006","journal-title":"Ann Fr Anesth Reanim"},{"issue":"2","key":"10.1111\/jth.15217_bb0565","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1080\/14397595.2019.1602241","article-title":"Danaparoid is effective and safe for patients with obstetric antiphospholipid syndrome","volume":"30","author":"Yoshihara","year":"2020","journal-title":"Mod Rheumatol"},{"issue":"16","key":"10.1111\/jth.15217_bb0570","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non\u2010vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1111\/jth.15217_bb0575","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/jth.13323","article-title":"Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH","volume":"14","author":"Martin","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"9","key":"10.1111\/jth.15217_bb0580","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1111\/jth.14948","article-title":"Fixed dose rivaroxaban can be used in extremes of bodyweight: a population pharmacokinetic analysis","volume":"18","author":"Speed","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1111\/jth.15217_bb0585","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/bjh.15756","article-title":"Progress in the monitoring of direct oral anticoagulant therapy","volume":"184","author":"Patel","year":"2019","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1111\/jth.15217_bb0590","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1182\/asheducation-2016.1.206","article-title":"Anti\u2010Xa monitoring of low\u2010molecular\u2010weight heparin in adult patients with cancer","volume":"2016","author":"Kreuziger","year":"2016","journal-title":"Hematology"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15217","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.15217","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622007103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622007103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15217","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:32:35Z","timestamp":1761535955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622007103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":117,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1538783622007103"],"URL":"https:\/\/doi.org\/10.1111\/jth.15217","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monitoring of anticoagulation in thrombotic antiphospholipid syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.15217","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 The Authors. Journal of Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of InternationalSociety on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}]}}